Use of linezolid in pediatrics: A critical review

International Journal of Infectious Diseases

Volumn 14, Issue 8, 2010, Pages

  Dotis, John ^a   Iosifidis, Elias ^a   Ioannidou, Maria ^a   Roilides, Emmanuel ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Children; Gram positive bacteria; Indications; Linezolid; Resistance

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ANEMIA; BACTERIAL INFECTION; BLOOD TOXICITY; BONE INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCARDITIS; HUMAN; LIVER TOXICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MYCOBACTERIOSIS; MYCOBACTERIUM; PATHOGENESIS; PEDIATRICS; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PNEUMONIA; RASH; REVIEW; SKIN DISEASE; SKIN INFECTION; SOFT TISSUE INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; ADOLESCENT; CASE REPORT; CHILD; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FEMALE; GRAM POSITIVE COCCI; GRAM-POSITIVE BACTERIAL INFECTIONS; INFANT; MALE; MICROBIOLOGY; NEWBORN; PRESCHOOL CHILD; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ACETAMIDES; ADOLESCENT; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 77955013215     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2009.10.002     Document Type: Review

References (57)

1. Diekema D.J., Jones R.N. Oxazolidinone antibiotics. Lancet 2001, 358:1975-1982.
2. Kaplan S.L., Deville J.G., Yogev R., Morfin M.R., Wu E., Adler S., et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003, 22:677-686.
3. Velissariou I.M. Use of linezolid in children: an overview of recent advances. Expert Rev Anti Infect Ther 2006, 4:947-952.
4. Kaplan S.L., Patterson L., Edwards K.M., Azimi P.H., Bradley J.S., Blumer J.L., et al. Linezolid for the treatment of community-acquired pneumonia in hospitalized children. Pediatr Infect Dis J 2001, 20:488-494.
5. Deville J.G., Adler S., Azimi P.H., Jantausch B.A., Morfin M.R., Beltran S., et al. Linezolid versus vancomycin in the treatment of known or suspected resistant Gram-positive infections in neonates. Pediatr Infect Dis J 2003, 22:S158-S163.
6. Wible K., Tregnaghi M., Bruss J., Fleishaker D., Naberhuis-Stehouwer S., Hilty M. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr Infect Dis J 2003, 22:315-323.
7. Godon N., Denizot S., Podevin G., Caillon J., Potel G., Christophe Roze J., et al. Effectiveness of linezolid and imipenem association in the treatment of severe community-acquired pneumonia in children: two case reports. Scand J Infect Dis 2006, 38:381-383.
8. Sullivan J., Tobias J.D. Preliminary experience with the use of oral linezolid in infants for the completion of antibiotic therapy in the outpatient setting after admission to the pediatric intensive care unit. Am J Ther 2006, 13:473-477.
9. Chen C.J., Chiu C.H., Lin T.Y., Lee Z.L., Yang W.E., Huang Y.C. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007, 26:985-988.
10. Travaglianti M., Pèrez M., Sberna N., Rousseau M., Calle G., Gómez S. Treatment of vancomycin-resistant Enterococcus with linezolid in paediatric hospitals. Farm Hosp 2007, 31:43-47.
11. Moylett E.H., Pacheco S.E., Brown-Elliott B.A., Perry T.R., Buescher E.S., Birmingham M.C., et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis 2003, 36:313-318.
12. Hoehn R., Groll A.H., Schaefer V., Bauer K., Schloesser R.L. Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates. Int J Antimicrob Agents 2006, 27:256-258.
13. Langgartner M., Mutenthaler A., Haiden N., Pollak A., Berger A. Linezolid for treatment of catheter-related cerebrospinal fluid infections in preterm infants. Arch Dis Child Fetal Neonatal Ed 2008, 93:397.
14. Hammerness P., Parada H., Abrams A., Linezolid: MAOI activity and potential drug interactions. Psychosomatics 2002, 43:248-249.
15. Roberts S.M., Freeman A.F., Harrington S.M., Holland S.M., Murray P.R., Zelazny A.M. Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy. Pediatr Infect Dis J 2006, 25:562-564.
16. Graham P.L., Abofo K., Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis 2002, 21:798-799.
17. Krueger W.A., Kottler B., Will B.E., Heininger A., Guggenberger H., Unertl K.E. Treatment of meningitis due to methicillin-resistant Staphylococcus epidermidis with linezolid. J Clin Microbiol 2004, 42:929-932.
18. Cook A.M., Ramsey C.N., Martin C.A., Pittman T. Linezolid for the treatment of a heteroresistant Staphylococcus aureus shunt infection. Pediatr Neurosurg 2005, 41:102-104.
19. Sabbatani S., Manfredi R., Frank G., Chiodo F. Linezolid in the treatment of severe central nervous system infections resistant to recommended antimicrobial compounds. Infez Med 2005, 13:112-119.
20. Viganó S.M., Edefonti A., Ferraresso M., Ranzi M.L., Grossi P., Righini A., et al. Successful medical treatment of multiple brain abscesses due to Nocardia farcinica in a paediatric renal transplant recipient. Pediatr Nephrol 2005, 20:1186-1188.
21. Anil M., Ozkalay N., Helvaci M., Agus N., Guler O., Dikerler A., et al. Meningitis due to Gemella haemolysans in a pediatric case. J Clin Microbiol 2007, 45:2337-2339.
22. Kumar S., Kohlhoff S., Valencia G., Hammerschlag M.R., Sharma R. Treatment of vancomycin-resistant Enterococcus faecium ventriculitis in a neonate. Int J Antimicrob Agents 2007, 29:740-741.
23. Milstone A.M., Dick J., Carson B., Siberry G.K. Cerebrospinal fluid penetration and bacteriostatic activity of linezolid against Enterococcus faecalis in a child with a ventriculoperitoneal shunt infection. Pediatr Neurosurg 2007, 43:406-409.
24. Ang J.Y., Lua J.L., Turner D.R., Asmar B.I. Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid. Pediatr Infect Dis J 2003, 22:1101-1103.
25. Matson K.L., Miller S.E. Tooth discoloration after treatment with linezolid. Pharmacotherapy 2003, 23:682-685.
26. Thomas C.R., Rosenberg M., Blythe V., Meyer W.J. Serotonin syndrome and linezolid. J Am Acad Child Adolesc Psychiatry 2004, 43:790.
27. Castagnola E., Moroni C., Gandullia P., Oddone M., Peri C., Casciaro R., et al. Catheter lock and systemic infusion of linezolid for treatment of persistent Broviac catheter-related staphylococcal bacteremia. Antimicrob Agents Chemother 2006, 50:1120-1121.
28. Gales A.C., Sader H.S., Andrade S.S., Lutz L., Machado A., Barth A.L. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int J Antimicrob Agents 2006, 27:300-302.
29. Ng P.C., Chow V.C., Lee C.H., Ling J.M., Wong H.L., Chan R.C. Persistent Staphylococcus capitis septicemia in a preterm infant. Pediatr Infect Dis J 2006, 25:652-654.
30. Park I.N., Hong S.B., Oh Y.M., Kim M.N., Lim C.M., Lee S.D., et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006, 58:701-704.
31. Thorell E.A., Sharma M., Jackson M.A., Selvarangan R., Woods G.M. Disseminated nontuberculous mycobacterial infections in sickle cell anemia patients. J Pediatr Hematol Oncol 2006, 28:678-681.
32. Javaheri M., Khurana R.N., O'hearn T.M., Lai M.M., Sadun A.A. Linezolid-induced optic neuropathy: a mitochondrial disorder?. Br J Ophthalmol 2007, 91:111-115.
33. Morales P., Ros J.A., Blanes M., Perez-Enguix D., Saiz V., Santos M. Successful recovery after disseminated infection due to Mycobacterium abscessus in a lung transplant patient: subcutaneous nodule as first manifestation-a case report. Transplant Proc 2007, 39:2413-2415.
34. Tan T.Q. Update on the use of linezolid: a pediatric perspective. Pediatr Infect Dis J 2004, 23:955-956.
35. Shaikh Z.H., Peloquin C.A., Ericsson C.D. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001, 33:375-379.
36. Villani P., Regazzi M.B., Marubbi F., Viale P., Pagani L., Cristini F., et al. Cerebrospinal fluid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002, 46:936-937.
37. Mutnick A.H., Biedenbach D.J., Turnidge J.D., Jones R.N. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY antimicrobial surveillance program, 1998-2000. Diagn Microbiol Infect Dis 2002, 43:65-73.
38. Rupprecht T.A., Pfister H.W. Clinical experience with linezolid for the treatment of central nervous system infections. Eur J Neurol 2005, 12:536-542.
39. Ntziora F., Falagas M.E. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007, 41:296-308.
40. Rana B., Butcher I., Grigoris P., Murnaghan C., Seaton R.A., Tobin C.M. Linezolid penetration into osteoarticular tissues. J Antimicrob Chemother 2002, 50:747-750.
41. Lovering A.M., Zhang J., Bannister G.C., Lankester B.J., Brown J.H., Narendra G., et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002, 50:73-77.
42. Rayner C.R., Baddour L.M., Birmingham M.C., Norden C., Meagher A.K., Schentag J.J. Linezolid in the treatment of osteomyelitis: results of compassionate use experience. Infection 2004, 32:8-14.
43. Birmingham M.C., Rayner C.R., Meagher A.K., Flavin S.M., Batts D.H., Schentag J.J. Linezolid for the treatment of multidrug-resistant. Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003, 36:159-168.
44. Munoz P., Rodriguez-Creixems M., Moreno M., Marin M., Ramallo V., Bouza E., et al. Linezolid therapy for infective endocarditis. Clin Microb Infect 2007, 13:211-215.
45. Brown-Elliot B.A., Ward S.C., Crist C.J., Mann L.B., Wilson R.W., Wallace R.J. In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother 2001, 45:1295-1297.
46. Chaudhry R., Mathur P., Dhawan B., Gaur S., Dey A.B. Infections caused by Gemella spp: case reports from India. J Infect 2001, 43:152-155.
47. Cerdá Zolezzi P., Rubio Calvo M.C., Millán L., Goñi P., Canales M., Capilla S., et al. Macrolide resistance phenotypes of commensal viridans group streptococci and Gemella spp and PCR detection of resistance genes. Int J Antimicrob Agents 2004, 23:582-589.
48. La Scola B., Raoult D. Molecular identification of Gemella species from three patients with endocarditis. J Clin Microbiol 1998, 36:866-871.
49. Centers for Disease Control and Prevention (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006; 55:301-5.
50. Alcala L., Ruiz-Serrano M.J., Perez-Fernandez Turegano C., Garcia de Viedma D., Diaz-Infantes M., Marin-Arriaza M., et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 2003, 47:416-417.
51. Rodriguez J.C., Cebrian L., Lopez M., Ruiz M., Jimenez I., Royo G. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004, 53:441-444.
52. Ntziora F., Falagas M.E. Linezolid for the treatment of patients with mycobacterial infections-a systematic review. Int J Tuberc Lung Dis 2007, 11:606-611.
53. Wallace R.J., Swenson J.M., Silcox V.A., Good R.C., Tschen J.A., Stone M.S. Spectrum of disease due to rapidly growing mycobacteria. Rev Infect Dis 1983, 5:657-679.
54. Anderegg T.R., Sader H.S., Fritsche T.R., Ross J.E., Jones R.N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) program. Int J Antimicrob Agents 2005, 26:13-21.
55. Mutnick A.H., Enne V., Jones R.N. Linezolid resistance since 2001: SENTRY antimicrobial surveillance program. Ann Pharmacother 2003, 37:769-774.
56. Saiman L., Goldfarb J., Kaplan S.A., Wible K., Edge-Padbury B., Naberhuis-Stehouwer S., et al. Safety and tolerability of linezolid in children. Pediatr Infect Dis J 2003, 22:S193-S200.
57. Meissner H.C., Townsend T., Wenman W., Kaplan S.L., Morfin M.R., Edge-Padbury B., et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003, 22:S186-S192.